General Control is a biotech company developing programmable epigenetic therapies that can precisely turn multiple genes on or off. Rather than cutting DNA, their synthetic transcription factors bind to specific regions of the genome to fine-tune gene expression with lasting effects. They’re targeting complex age-related diseases like obesity, liver fibrosis, and muscle decline by adjusting entire genetic networks, not just single proteins. Their goal is to create durable, one-time (or infrequent) treatments—moving beyond traditional drugs—to rewrite cellular behavior in a controlled and safe way.